Transactions
15
Insider / GILEAD SCIENCES, INC.
Berger Dietmar
Chief Medical Officer at GILEAD SCIENCES, INC.
- Company
- GILEAD SCIENCES, INC.
- Ticker
- GILD
- First filing on record
- January 5, 2026
- Latest trade on record
- September 10, 2026
- SEC filings
- EDGAR ↗
Berger Dietmar, Chief Medical Officer at GILEAD SCIENCES, INC., has disclosed 15 transactions in GILD since January 5, 2026: 0 purchases (0 open-market buys) and 4 sales, worth about $1.1M at the reported prices. The latest was filed September 11, 2026, 1 day after the trade.
Open-market buys
0
Sales
4
Avg. disclosure lag
1.9d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Berger Dietmar made no purchases and 4 sales worth $1.1M, plus 11 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Berger Dietmar has traded 1 stock on record; the largest by dollars is GILD.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 5 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 8 | 39,050 | — |
| F | Shares withheld for tax | 4 | 8,533 | $1.1M |
| A | Grant or award | 3 | 48,420 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 15 | 0 | 4 · $1.1M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| GILD | Option / conversion M | September 10, 2026 | September 11, 2026 | 1d | 533 | — | — | derivative | Form 4 ↗ | |
| GILD | Sell F | September 10, 2026 | September 11, 2026 | 1d | 263 | $145 | $38K | Form 4 ↗ | ||
| GILD | Option / conversion M | September 10, 2026 | September 11, 2026 | 1d | 533 | — | — | Form 4 ↗ | ||
| GILD | Option / conversion M | June 10, 2026 | June 11, 2026 | 1d | 533 | — | — | derivative | Form 4 ↗ | |
| GILD | Sell F | June 10, 2026 | June 11, 2026 | 1d | 263 | $121 | $32K | Form 4 ↗ | ||
| GILD | Option / conversion M | June 10, 2026 | June 11, 2026 | 1d | 533 | — | — | Form 4 ↗ | ||
| GILD | Other A | March 10, 2026 | March 12, 2026 | 2d | 31,475 | — | — | derivative | Form 4 ↗ | |
| GILD | Other A | March 10, 2026 | March 12, 2026 | 2d | 8,415 | — | — | derivative | Form 4 ↗ | |
| GILD | Option / conversion M | March 10, 2026 | March 12, 2026 | 2d | 2,133 | — | — | derivative | Form 4 ↗ | |
| GILD | Sell F | March 10, 2026 | March 12, 2026 | 2d | 1,063 | $149 | $158K | Form 4 ↗ | ||
| GILD | Option / conversion M | March 10, 2026 | March 12, 2026 | 2d | 2,133 | — | — | Form 4 ↗ | ||
| GILD | Other A | February 27, 2026 | March 2, 2026 | 3d | 8,530 | — | — | Form 4 ↗ | ||
| GILD | Option / conversion M | January 2, 2026 | January 5, 2026 | 3d | 16,326 | — | — | derivative | Form 4 ↗ | |
| GILD | Sell F | January 2, 2026 | January 5, 2026 | 3d | 6,944 | $122 | $844K | Form 4 ↗ | ||
| GILD | Option / conversion M | January 2, 2026 | January 5, 2026 | 3d | 16,326 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| September 11, 2026 | Form 4 | 0001739515-26-000011 | 3 | published | EDGAR ↗ |
| June 11, 2026 | Form 4 | 0001739515-26-000008 | 3 | published | EDGAR ↗ |
| March 12, 2026 | Form 4 | 0001739515-26-000006 | 5 | published | EDGAR ↗ |
| March 2, 2026 | Form 4 | 0001739515-26-000004 | 1 | published | EDGAR ↗ |
| January 5, 2026 | Form 4 | 0001739515-26-000002 | 3 | published | EDGAR ↗ |
Other insiders at GILEAD SCIENCES, INC.
- Mercier Johanna Chief Commercial Officer 51 rows
- O'Day Daniel Patrick Chairman & CEO 49 rows
- Dickinson Andrew D Chief Financial Officer 30 rows
- Bluestone Jeffrey Director 20 rows
- Cain Wettan Keeley M EVP Gen Counsel, Legal & Comp 15 rows
- Telman Deborah H Director 13 rows
- Kramer Kelly A. Director 12 rows
- WELTERS ANTHONY Director 10 rows
- Rodriguez Javier Director 7 rows
- Horning Sandra Director 6 rows
Everyone on file, with contracts and lobbying under the company's name: GILEAD SCIENCES, INC..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 5 | 15 | January 5, 2026 | September 11, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.